Summit Therapeutics Inc. — Director's Dealing 2021

Nov 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2021-11-03

Reporting Person: Gayko Urte (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-03	Stock Option (right to buy)	$5.54	A	200000	Acquired	2031-11-03	Common Stock (200000)	Direct
2021-11-03	Stock Option (right to buy)	$5.54	A	4041	Acquired	2031-11-03	Common Stock (4041)	Direct

Footnotes

F1: The option was granted on November 3, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on November 3, 2022.

F2: The option was granted on November 3, 2021 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021.

F3: Not applicable.